TScan Therapeutics Inc
TCRX
查看详细走势图
1.030USD
+0.120+13.14%
收盘 02/06, 16:00（美东）报价延迟15分钟
58.45M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+13.14%
5天
+0.98%
1月
-12.71%
6月
-37.20%
今年开始到现在
+3.00%
1年
-52.75%
查看详细走势图
TradingKey TScan Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
TScan Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名109/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.00。中期看，股价处于平稳状态。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
TScan Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
TScan Therapeutics Inc亮点
亮点风险
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
业绩增长期
公司处于发展阶段，最新年度总收入2.82M美元
利润高增长
公司净利润处于行业前列，最新年度总收入2.82M美元
估值高估
公司最新PE估值-0.92，处于3年历史高位
机构减仓
最新机构持股39.04M股，环比减少22.03%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值829.92K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.36
分析师目标
根据
7
位分析师
买入
评级
7.000
目标均价
+579.61%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
TScan Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
TScan Therapeutics Inc简介
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
公司代码TCRX
公司TScan Therapeutics Inc
CEOMacbeath (Gavin)
网址https://www.tscan.com
相关品种
